AFFILIATED MANAGERS GROUP $168.01

When it comes to assessing the outlook for drugmakers, investors really only care about the pipeline of new drugs. After all, existing drugs eventually lose patent protection, and when that happens, a large hole in the income statement can appear. Just a few days ago, I looked at the prospects for traditional drugmakers and concluded that Bristol-Myers Squibb (NYSE: BMY) and Eli Lilly (NYSE: LLY) are among the handful of Big Pharma firms with appealing pipelines. The renewed pipelines are in some instances giving those stocks a solid boost, with shares rising at an impressive pace over the past year.

Rotate into the outperforming biotech sector with these three ETFs.

As we enter the bumpy summer months, large-cap US domestic stocks and health-care names are on Louis Navellier's list, and he shares several to watch.I'm talking with Louis Navellier and he's kind enough to share some great recommendations with us today.

Alnylam has already seen a big run, but clinical success could bring even more gains.

Amgen really needs the pipeline to come through to support this valuation.